PSTX - Poseida Therapeutics, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.3600 |
| Open | 2.3500 |
| Bid | 2.3500 x 3000 |
| Ask | 2.4400 x 3200 |
| Day's Range | 2.2950 - 2.4200 |
| 52 Week Range | 1.9500 - 8.8200 |
| Volume | |
| Avg. Volume | 694,416 |
| Market Cap | 206.526M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3800 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.40 |
Fair Value
Related Research
PR NewswirePoseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President of Gene Therapy, Brent Warner, will participate in a virtual fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day on Tuesday, May 30, 2023 at 12:00pm PT | 03:00pm ET.
- PR Newswire
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that two abstracts have been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), being held in Montreal, Canada and virtually on June 24-28, 2023.
- PR Newswire
Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlights its two oral and four poster presentations on the Company's preclinical gene therapy programs and platforms at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually May 16 – 20, 2023.
Simply Wall St.Poseida Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Poseida Therapeutics ( NASDAQ:PSTX ) First Quarter 2023 Results Key Financial Results Revenue: US$10.3m (up by US$8.91m...
ZacksWhat Makes Poseida Therapeutics, Inc. (PSTX) a New Buy Stock
Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksPoseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Tops Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -12.50% and 3.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.
- PR Newswire
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that six data presentations, including two oral presentations, highlighting the Company's preclinical gene therapy programs and platforms will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, being held at the Los Angeles Convention Center in Los Angeles and virtually on
- PR Newswire
Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that it will participate in the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:15pm PT | 6:15pm ET in Las Vegas.
- Simply Wall St.
Benign Growth For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Underpins Stock's 44% Plummet
To the annoyance of some shareholders, Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares are down a considerable 44% in...
- PR Newswire
Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Rafael G. Amado, M.D., to its Board of Directors, effective today.
- PR Newswire
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Compensation Committee of its Board of Directors granted an inducement award to Kristin Yarema, the Company's new President, Cell Therapy. This grant is made pursuant to the Company's 2022 Inducement Plan as an inducement material to Ms. Yarema entering into employment with the Company in accordance with
- PR Newswire
Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Kristin Yarema, Ph.D., has joined the Company as President, Cell Therapy effective today.
- Simply Wall St.
With 46% stake, Poseida Therapeutics, Inc. (NASDAQ:PSTX) seems to have captured institutional investors' interest
Key Insights Given the large stake in the stock by institutions, Poseida Therapeutics' stock price might be vulnerable...
ZacksPoseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Misses Revenue Estimates
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -182.98% and 71.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the fourth quarter and full year ended December 31, 2022.
- PR Newswire
Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of five new members to its Gene Therapy Scientific Advisory Board (SAB). These world-class researchers will join George M. Church, Ph.D., Chair of Poseida's recently formed Gene Therapy SAB, to provide counsel on the Company's gene therapy programs in development.
- PR Newswire
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT.
- Simply Wall St.
Poseida Therapeutics (NASDAQ:PSTX) shareholders are still up 91% over 1 year despite pulling back 10.0% in the past week
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
ZacksHere's What Could Help Poseida Therapeutics, Inc. (PSTX) Maintain Its Recent Price Strength
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- PR Newswire
Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's Chief Executive Officer, Mark Gergen, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET.
- PR Newswire
Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 22, 2023.
- PR Newswire
Poseida Therapeutics Announces Board Change
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that Eric Ostertag, M.D., Ph.D., has resigned as Executive Chairman and will retire from the Board of Directors effective February 3, 2023. However, Dr. Ostertag will continue as a consultant to the Company to advise on technical and scientific matters.
ZacksPoseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable
Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
InvestorPlaceHow to Nab a 78% Gain in 8 Weeks
Luke Lango’s PSTX trade takes off … what went into the recommendation? … analyzing a trade that could be on the verge of a blast-off … are you willing to follow price-action exclusively? Let’s begin with the chart of a biotech company called Poseida Therapeutics (PSTX).As you look at this 30-month chart, what do you see?Specifically, as of late-November last year, was it a good time to enter a bullish trade on Poseida? Source: StockCharts.com Hold onto your answer for a moment. We’ll circle back